Growth Hormone Deficiency in Cancer Survivors

In the final episode, the panel addresses one of the most clinically complex and emotionally charged questions in GHD management: when and how to initiate or resume GH therapy in patients with a history of malignancy.

Dr. Agrawal poses the question of GH use in the setting of active or recent malignancy, noting that in adult practice, the standard approach is to wait at least 5 years post-remission before initiating GH — with a multidisciplinary decision involving the oncology team. One exception is non-melanoma skin cancers, which are considered lower-risk for GH-related stimulation.

Dr. Alter explains the pediatric approach, which is institution-dependent and individualized. At Children’s Hospital of Philadelphia, for non-craniopharyngioma malignancies (e.g., germ cell tumors), the team waits 2 years from tumor stability, documents neuro-oncology consensus, and monitors with MRI at 6-month intervals. For craniopharyngiomas, evidence now supports initiating GH as early as 6 months post-treatment, given that no excess tumor recurrence risk has been observed. Age matters: a 3-year-old has more time to wait; a 14-year-old in a critical growth window may not.

Dr. Garcia frames the informed consent conversation for adult cancer survivors: patients must understand that having a prior malignancy (and its treatments, including radiation) already elevates the risk of secondary cancers — and that current data do not show GH adding further risk beyond that baseline. However, these conversations must acknowledge genuine uncertainty, and patients must be active partners in the decision.

Thank you for watching this HCP Live Peer Exchange series on growth hormone deficiency. Please subscribe to our eNewsletter for information on upcoming video series.